bioMérieux – Business review for the nine months ended September 30, 2015

22 Ottobre, 2015

  •  Robust growth in nine-month sales:
    •  Sales reached €1,412 million
    •  Up 18.3% as reported
    • Up 8.3% at constant exchange rates and scope of consolidation
  • Solid momentum in the Americas and EMEA1 regions in the third quarter
  • Significant operational advances:
    • FDA clearance of the 4th FilmArray® panel: Meningitis/Encephalitis
    • Commercial launch of VIDAS® 3 in the United States
    • Deployment of capital expenditures as planned
  • Organic sales growth objective should end the year around 6.5%
Alexandre Mérieux, Chief Executive Officer, said: "bioMérieux continued to drive very satisfactory organic sales growth over the first nine months of the year, with a more than 8% gain for the period. This sales performance reflects our effectively balanced product portfolio and geographic positions, as well as FilmArray®’s remarkable performance. Given this robust growth dynamic and based on our nine-month sales, organic sales growth objective should end the year around 6.5%."
 
 
1 Europe – Middle East – Africa
Scaricare
Pioneering diagnostics